… Anolli: nothing to disclose. Pietro Lampertico: advisor and speaker bureau for BMS, Roche,
… How to cite this article: Degasperi E, Anolli MP, Lampertico P. Bulevirtide for patients with …

In light of the policy debate on too-big-to-fail we investigate evidence of economies of scale
for 103 European listed banks over 2000–2011. Using the Stochastic Frontier Approach, the …

Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the
development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)…

Background & Aims As the long-term benefits of a sustained virological response (SVR) in
HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we …

Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until
recently, the only therapeutic approach has been the off‐label use of a 48 weeks course of …

Background & Aims Bulevirtide (BLV) has recently been conditionally approved for the
treatment of chronic hepatitis delta (CHD) in Europe, but its effectiveness and safety in patients …

Bulevirtide recently received conditional approval from the EMA for the treatment of chronic
hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first …

Background and Aim The World Health Organization (WHO) goal of hepatitis C virus (HCV)
elimination by 2030 relies on the scaling‐up of both identification and linkage to care of the …

This paper explores the ability of financial analysts to gauge the risk taken by banks and
investigates the impact of the recent financial crisis. Using a sample of 36,343 forecasts issued …

Background and Aim Management of chronic hepatitis delta (CHD) requires reliable tests
for HDV RNA quantification. The aim of the study was to compare two extraction methods for …